We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$4.46B
This Fund
S&P 500
This Quarter
Est. Return
+3.74%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.09B
AUM Growth
+$101M
(+5.1%)
Cap. Flow
+$73.1M
Cap. Flow
% of AUM
3.49%
Top 10 Holdings %
Top 10 Hldgs %
52.15%
Holding
437
New
42
Increased
236
Reduced
93
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$23.6M |
| 2 |
Microsoft
MSFT
|
+$18.5M |
| 3 |
NVIDIA
NVDA
|
+$17.6M |
| 4 |
Amazon
AMZN
|
+$15.6M |
| 5 |
Meta Platforms (Facebook)
META
|
+$14.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pinduoduo
PDD
|
+$92.1M |
| 2 |
KE Holdings
BEKE
|
+$15.6M |
| 3 |
TSMC
TSM
|
+$9.67M |
| 4 |
Full Truck Alliance
YMM
|
+$9.6M |
| 5 |
Tencent Music
TME
|
+$8.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.79% |
| 2 | Consumer Discretionary | 26.64% |
| 3 | Communication Services | 10.64% |
| 4 | Healthcare | 6.89% |
| 5 | Financials | 6.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
MannKind Corp
MNKD
$1.27B
| $124K | 0.01% |
24,667
+2,628
| +12% | +$14.7K |
|
377
Nurix Therapeutics
NRIX
$2.72B
| $122K | 0.01% |
+10,288
| New | +$172K |
|
378
Myriad Genetics
MYGN
$302M
| $122K | 0.01% |
13,720
+1,968
| +17% | +$23.6K |
|
379
Intellia Therapeutics
NTLA
$1.8B
| $120K | 0.01% |
16,831
-1,222
| -7% | -$12.3K |
|
380
Vir Biotechnology
VIR
$1.83B
| $104K | 0.01% |
+15,993
| New | +$142K |
|
381
Ford
F
$55.3B
| $102K | ﹤0.01% |
10,208
| – | – |
|
382
Anavex Life Sciences
AVXL
$277M
| $102K | ﹤0.01% |
+11,911
| New | +$112K |
|
383
Rocket Pharmaceuticals
RCKT
$424M
| $97.2K | ﹤0.01% |
14,567
+3,513
| +32% | +$34.7K |
|
384
Cogent Biosciences
COGT
$6.02B
| $93.9K | ﹤0.01% |
15,670
+4,290
| +38% | +$33.6K |
|
|
ETNB
385
DELISTED
89bio
ETNB
| $93.3K | ﹤0.01% |
+12,827
| New | +$112K |
|
386
ImmunityBio
IBRX
$8.53B
| $91.3K | ﹤0.01% |
30,331
-8,569
| -22% | -$26K |
|
|
DAWN
387
DELISTED
Day One Biopharmaceuticals
DAWN
| $88.3K | ﹤0.01% |
11,136
-140
| -1% | -$1.51K |
|
388
Arcus Biosciences
RCUS
$3.72B
| $82.4K | ﹤0.01% |
+10,498
| New | +$122K |
|
389
Kura Oncology
KURA
$1.13B
| $80.9K | ﹤0.01% |
12,252
+1,951
| +19% | +$15.2K |
|
390
Cheche Group
CCG
$38.6M
| $70.5K | ﹤0.01% |
+2,373
| New | +$80.5K |
|
391
Altimmune
ALT
$605M
| $67.1K | ﹤0.01% |
13,427
+2,268
| +20% | +$14.4K |
|
392
Emergent Biosolutions
EBS
$303M
| $50.5K | ﹤0.01% |
10,383
+145
| +1% | +$1.2K |
|
393
Relay Therapeutics
RLAY
$4.11B
| $50.2K | ﹤0.01% |
19,165
+1,511
| +9% | +$5.92K |
|
|
VERV
394
DELISTED
Verve Therapeutics
VERV
| $48.1K | ﹤0.01% |
+10,522
| New | +$70.5K |
|
395
Akebia Therapeutics
AKBA
$243M
| $37.1K | ﹤0.01% |
19,311
+6,595
| +52% | +$13.5K |
|
396
Sana Biotechnology
SANA
$1.18B
| $30.6K | ﹤0.01% |
18,236
-3,966
| -18% | -$11.1K |
|
397
Humacyte
HUMA
$181M
| $29.2K | ﹤0.01% |
17,133
+788
| +5% | +$2.96K |
|
398
Scilex Holding
SCLX
$38.2M
| $7.81K | ﹤0.01% |
898
| – | – |
|
399
Arbutus Biopharma
ABUS
$1B
| – | – |
-10,385
| Closed | -$34K |
|
400
Allogene Therapeutics
ALLO
$698M
| – | – |
-25,992
| Closed | -$55.4K |
|
Similar funds
ACM
HCM
MAM
AP
BP
WSFS
AOI
WA
E Fund Management's Q1 2025 Portfolio in Review
As of Q1 2025, E Fund Management held 437 positions worth $2.09B, up 5.1% from $1.99B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
E Fund Management deployed $73.1M of net new capital in Q1 2025, opening 42 new positions and adding to 236 existing holdings. Its largest new stake was abrdn Physical Gold Shares ETF: 119,505 shares worth $3.56M.
By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 40% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Pinduoduo, an estimated $92.1M trimmed.
- E Fund Management's largest Q1 2025 buy was abrdn Physical Gold Shares ETF: 119,505 shares worth $3.56M.
- E Fund Management added most to Apple in Q1 2025, an estimated $23.6M increase.
- E Fund Management's biggest Q1 2025 reduction was Pinduoduo, cutting an estimated $92.1M.
- E Fund Management fully exited iShares MSCI Global Gold Miners ETF in Q1 2025, selling an estimated $3.03M.
- E Fund Management's ten largest holdings make up 52% of its $2.09B portfolio in Q1 2025.
- E Fund Management opened 42 new positions and closed 39 in Q1 2025.
- E Fund Management's portfolio value rose 5.1% quarter-over-quarter to $2.09B.
Based on E Fund Management's 13F filing for Q1 2025, filed 13 May 2025.